Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2015

View Archived Issues

Ablynx achieves preclinical PoC with Nanobody construct in Merck & Co. collaboration

Autotelic acquires rights to trabedersen from Isarna

RXi Pharmaceuticals reports interim data from phase IIa study of RXI-109

New company Decibel Therapeutics launched to address hearing loss

Novartis introduces JAK/TYK2 inhibitors

Actelion presents prostaglandin D2 receptor 2 antagonists

Rock Creek completes phase I trial of oral formulations of anatabine citrate

Novo Nordisk licenses use of Emisphere's Eligen technology for oral drug development

Sanofi Pasteur and IDRI create Global Health Vaccine Center of Innovation

Integral Molecular's Ebola antibody research supported by new NIAID award

Johnson & Johnson updates progress of third quarter 2015

Studies in vivo support clinical development of novel anti-miR-103/107 candidate RG-125

AbbVie's ABT-555 enters clinical evaluation for multiple sclerosis

Galapagos advances triple combination therapy in cystic fibrosis under AbbVie collaboration

FDA places partial clinical hold on beloranib

FDA approves Praxbind as dabigatran reversal agent

Genentech presents results from clinical trials of its anti-influenza antibody MHAA-4549A

Orion patents TRPA1 antagonists

Zheijiang University and Shanghai Institute of Materia Medica disclose PKB inhibitors

Merck KGaA and Cancer Research Technology divulge Wnt signaling inhibitors

Shionogi introduces anti-HIV agents

Lexicon describes orally active small-molecule inhibitors of NOTUM

New molecular probe [18F]5-FPN could be useful for melanoma diagnosis and staging

Phase I results for SUVN-G3031, a candidate to treat Alzheimer's disease

FDA requests additional data for lifitegrast NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.